272 Capital’s Mesa Laboratories MLAB Stock Holding History

272 Capital’s Portfolio MLAB Stock Details MLAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,190	Closed	-$1.19M	–	94
2023 Q4	$1.19M	Buy	+12,190	New	+$1.19M	0.4%	47

Other funds holding MLAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BCM

Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return

272 Capital's MLAB Position: Q1 2024 in Review

272 Capital sold out of Mesa Laboratories (MLAB) in Q1 2024, closing a stake of 12,190 shares — an estimated $1.19M sold.

272 Capital first reported a position in MLAB in Q4 2023 and held it in 1 quarter. The position peaked at $1.19M in Q4 2023. 155 funds tracked by Wall St. Rank hold MLAB as of Q1 2024.

272 Capital reported no remaining Mesa Laboratories position as of Q1 2024 after selling out during the quarter.
272 Capital sold 12,190 Mesa Laboratories shares in Q1 2024, an estimated $1.19M.
272 Capital first reported a position in Mesa Laboratories in Q4 2023 and held it in 1 quarter.
272 Capital's Mesa Laboratories position peaked at $1.19M in Q4 2023.
155 funds tracked by Wall St. Rank held Mesa Laboratories as of Q1 2024.

Based on 272 Capital's 13F filing for Q1 2024, filed 15 May 2024.